Thalia Therapeutics (LSE:THAT) 10-Year Share Buyback Ratio: -32.30% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Thalia Therapeutics 10-Year Share Buyback Ratio?

Thalia Therapeutics LSE:THAT 10-Year Share Buyback Ratio is -32.30 as of Dec. 2025. The stock has 1 warning sign investors should review. Among 666 Biotechnology companies, Thalia Therapeutics ranks worse than 78.38% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Thalia Therapeutics's current 10-Year Share Buyback Ratio was -32.30%.

LSE:THAT's 10-Year Share Buyback Ratio is ranked worse than
78.38% of 666 companies
in the Biotechnology industry
Industry Median: -11.9 vs LSE:THAT: -32.30

Thalia Therapeutics (LSE:THAT) 10-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Thalia Therapeutics 10-Year Share Buyback Ratio Related Terms

LSE:THAT vs VRTX, REGN, MRNA: 10-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Thalia Therapeutics's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thalia Therapeutics 10-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thalia Therapeutics's 10-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Thalia Therapeutics's 10-Year Share Buyback Ratio falls into.


Thalia Therapeutics 10-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 10-Year Share Buyback Ratio of -32.30 mean?
Thalia Therapeutics (LSE:THAT) has a 10-Year Share Buyback Ratio of -32.30 as of Dec. 2025. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Thalia Therapeutics and its competitors. According to the industry distribution chart, Thalia Therapeutics ranks #522 out of 666 companies in the Biotechnology industry, placing it in the top 78.4%.
Is Thalia Therapeutics' 10-Year Share Buyback Ratio too high?
Thalia Therapeutics' current 10-Year Share Buyback Ratio is -32.30. Based on the distribution chart, Thalia Therapeutics ranks #522 out of 666 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Thalia Therapeutics' 10-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Thalia Therapeutics ranks #522 out of 666 companies for 10-Year Share Buyback Ratio. This places Thalia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Thalia Therapeutics and its competitors. Thalia Therapeutics's current 10-Year Share Buyback Ratio is -32.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thalia Therapeutics stock overvalued right now?
Thalia Therapeutics (LSE:THAT) has a current 10-Year Share Buyback Ratio of -32.30. The current 10-Year Share Buyback Ratio is -32.30. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Thalia Therapeutics (LSE:THAT), the current 10-Year Share Buyback Ratio is -32.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thalia Therapeutics Business Description

Other Exchanges 0GO:Germany
Address 2 Portman Street, London, GBR, W1H 6DU
Thalia Therapeutics PLC is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. Its pipeline includes a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a) [Lp(a)], which are established risk factors for cardiovascular disease.